{"id":938596,"date":"2026-02-19T19:16:19","date_gmt":"2026-02-20T00:16:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/prospective-validation-study-in-jaad-demonstrates-castle-biosciences-advancead-tx-test-identifies-patients-more-likely-to-achieve-faster-and-deeper-responses-with-jak-inhibitor-thera\/"},"modified":"2026-02-19T19:16:19","modified_gmt":"2026-02-20T00:16:19","slug":"prospective-validation-study-in-jaad-demonstrates-castle-biosciences-advancead-tx-test-identifies-patients-more-likely-to-achieve-faster-and-deeper-responses-with-jak-inhibitor-thera","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/prospective-validation-study-in-jaad-demonstrates-castle-biosciences-advancead-tx-test-identifies-patients-more-likely-to-achieve-faster-and-deeper-responses-with-jak-inhibitor-thera\/","title":{"rendered":"Prospective Validation Study in JAAD Demonstrates Castle Biosciences\u2019 AdvanceAD-Tx\u2122 Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis"},"content":{"rendered":"

\nStudy data show that AdvanceAD-Tx can stratify patients by molecular profile identifying those more likely to achieve near-clear skin (EASI-90), faster time to response and meaningful patient-reported benefits when treated with JAK inhibitor therapy compared to a Th2-targeted therapy
\n<\/h2>\n
\n

FRIENDSWOOD, Texas, Feb. 19, 2026 (GLOBE NEWSWIRE) — Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a prospective, multicenter clinical validation study in the\u00a0Journal of the American Academy of Dermatology<\/em> (JAAD) demonstrating that its AdvanceAD-Tx test can identify patients with moderate-to-severe atopic dermatitis (AD) who are significantly more likely to achieve greater and faster clinical responses when treated with a Janus kinase inhibitor (JAKi) compared to T helper type 2 (Th2)-targeted therapies.1<\/sup><\/p>\n

\u201cAtopic dermatitis can look similar on the surface, but the biology driving the disease can differ meaningfully from patient to patient,\u201d said Mark G. Lebwohl, M.D., senior study author, dean for clinical therapeutics and professor and chairman emeritus of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York. \u201cThis study shows that AdvanceAD-Tx can provide objective molecular insight to help clinicians better align systemic therapy choices with an individual patient\u2019s disease biology earlier in the treatment journey and improve outcomes that matter to patients.\u201d<\/p>\n

AdvanceAD-Tx is a non-invasive gene expression profile test designed to provide objective molecular insight to help guide systemic treatment decision making for patients 12 years of age and older with moderate-to-severe AD who are considering systemic therapy. Using simple lesional skin scrapings, no biopsy required, the test evaluates the expression of 487 genes across 12 inflammatory and cutaneous biology pathways and reports one of two actionable molecular profiles \u2014 a JAK Inhibitor Responder Profile or a Th2 Molecular Profile \u2014 to help clinicians better understand the underlying immune biology of an individual patient\u2019s disease.<\/p>\n

Results from the independent validation cohort demonstrated that approximately 30 percent of patients studied were identified by the AdvanceAD-Tx test as having a JAK Inhibitor Responder Profile. Among these patients, those treated with a JAKi were 5.5 times more likely to achieve at least 90 percent improvement in Eczema Area and Severity Index (EASI-90) by three months compared to those treated with Th2\u2013targeted therapies (45.5% vs. 8.3%, p=0.021), and they achieved a response nearly four times faster (p=0.049). Patients with a JAK Inhibitor Responder Profile who were treated with a JAKi were also significantly more likely to:<\/p>\n